Stock Market Reviews

IBIO (iBio, Inc.) News

Get the latest news, insights, and market updates on IBIO (iBio, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• iBio Unveils New Non-Human Primate Data on IBIO-610, an Activin E Antibody with Strong Therapeutic Potential for Fat-Selective Weight-Loss and Weight Maintenance
  Previously reported data showed that in a diet-induced obesity mouse model, IBIO-610 drives fat-selective, GLP-1-synergistic weight loss and prevents weight regain following GLP-1 treatment discontinuation New non-human primate data projects a human half-life of up to 100 days, potentially enabling treatment with only twice-yearly dosing Extended half-life data and differentiated mechanism of action reinforce IBIO-610’s potential as a leading next-generation therapy for obesity and cardiometabol
  Oct 30, 2025 - $IBIO
• iBio to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
  SAN DIEGO, Oct. 23, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), an AI-driven innovator of precision antibody therapies, today announced that it will participate in the Guggenheim 2nd Annual Healthcare Innovation Conference, taking place November 10–12, 2025 in Boston. Martin Brenner, DVM, Ph.D., Chief Executive Officer and Chief Scientific Officer of iBio, will participate in a fireside chat on Monday, November 10, 2025, at 8:30 a.m. ET to discuss the Company’s continued development in b
  Oct 23, 2025 - $IBIO
• iBio to Present New Preclinical Data on Its Activin E Antibody at Two Upcoming Scientific Conferences, ObesityWeek® and PEGS Europe 2025
  SAN DIEGO, Oct. 21, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator of precision antibody therapies, today announced that Cory Schwartz, Ph.D., Director of Research and Early Development at iBio, will deliver an oral presentation at ObesityWeek 2025 November 4-7 in Atlanta. In addition, Martin Brenner, DVM, Ph.D., Chief Executive Officer and Chief Scientific Officer of iBio, will deliver an oral presentation at PEGS Europe 2025 November 11–13 in Lisbon. “We are excited
  Oct 21, 2025 - $IBIO
• iBio Full Year 2025 Earnings: US$1.75 loss per share (vs US$4.03 loss in FY 2024)
  iBio ( NASDAQ:IBIO ) Full Year 2025 Results Key Financial Results Net loss: US$18.4m (loss widened by 19% from FY...
  Sep 6, 2025 - $IBIO
• iBio Reports Fiscal Year 2025 Financial Results and Provides Corporate Update
  SAN DIEGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator of precision antibody therapies, today announced its financial results for the fiscal year ended June 30, 2025, and provided a corporate update on its progress. “This fiscal year has been transformative for iBio as we advanced both our pipeline and corporate strategy,” said Martin Brenner, Ph.D., DVM, Chief Executive Officer and Chief Scientific Officer of iBio. “We began building a differentiated prec
  Sep 5, 2025 - $IBIO
• iBio Announces Closing of $50 Million Public Offering
  Total gross proceeds of $100 million if all Series G warrants and Series H warrants are exercised for cash Financing was led by Balyasny Asset Management and included participation from Cormorant Asset Management, Adage Capital Partners LP, Ally Bridge Group, Marshall Wace, Coastlands Capital, SilverArc Capital Management, Vestal Point Capital, and Ausangate Capital SAN DIEGO, Aug. 25, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (Nasdaq: IBIO), an AI-driven innovator of precision antibody therapies, tod
  Aug 25, 2025 - $IBIO
• iBio Announces Pricing of $50 Million Public Offering
  SAN DIEGO, Aug. 19, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (Nasdaq: IBIO), an AI-driven innovator of precision antibody therapies, today announced the pricing of an underwritten public offering (the “offering”) of (i) pre-funded warrants to purchase 71,540,000 shares of iBio’s common stock (the “pre-funded warrants”), and (ii) accompanying Series G warrants representing the right to purchase (the “Series G warrants”) (a) 35,770,000 shares of iBio’s common stock, or pre-funded warrants in lieu there
  Aug 19, 2025 - $IBIO
• iBio Announces Proposed Public Offering
  SAN DIEGO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (Nasdaq: IBIO), an AI-driven innovator of precision antibody therapies, today announced it has commenced an underwritten public offering (the “offering”) of (i) pre-funded warrants to purchase shares of iBio’s common stock, and (ii) accompanying Series G warrants each representing the right to purchase (a) a fraction of a share of iBio’s common stock, or a pre-funded warrant in lieu thereof, and (b) Series H warrants each representing the r
  Aug 18, 2025 - $IBIO
• iBio and AstralBio Unveil Obesity Program with Novel Amylin Agonist Antibody Demonstrating Promising In Vivo Results
  Lead amylin receptor agonist engineered antibody significantly reduced acute food intake in a mouse model of obesity, comparable to the efficacy of a leading amylin peptide agonist Findings support the potential of antibody-based agonists to address the growing demand for safer, longer-acting treatments for obesity and cardiometabolic diseases Conference call today, June 24 at 8:30 a.m. ET to discuss new pre-clinical data and obesity pipeline SAN DIEGO, June 24, 2025 (GLOBE NEWSWIRE) -- iBio, In
  Jun 24, 2025 - $IBIO
• iBio Presents Next-Generation Obesity and Cardiometabolic Pipeline Candidates on June 24 Conference Call
  Review of promising Myostatin and Activin E antibody data iBio to announce 3rd target in Astral Bio Collaboration Conference call Tuesday, June 24 at 8:30 a.m. ET SAN DIEGO, June 23, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (Nasdaq: IBIO), an AI-driven innovator of precision antibody therapies, today announced the Company will host a conference call on Tuesday, June 24, at 8:30 a.m. ET to review its latest advances in obesity and cardiometabolic disease treatments and announce a third target in the A
  Jun 23, 2025 - $IBIO